Test to Treat TB: Impact of Sputum Sequencing-guided Individualised Therapy on Outcomes in Drug-resistant Tuberculosis

NANot yet recruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

July 31, 2027

Conditions
Tuberculosis, Multidrug-Resistant
Interventions
DIAGNOSTIC_TEST

Targeted sequencing using the GenoScreen Deeplex assay

Targeted sequencing to be performed on DNA extracted directly from clinical sputum samples using an on-demand strategy to generate a drug resistant profile. Clinicians treating the patients will have access to this and prescribe 5 or more effective drugs to the patients within 14 days of diagnosis.

Trial Locations (1)

Unknown

University of Cape Town, Cape Town

All Listed Sponsors
collaborator

University of Stellenbosch

OTHER

collaborator

Ospedale San Raffaele

OTHER

collaborator

Stichting Katholieke Universiteit

OTHER

collaborator

University of Cape Town Lung Institute

OTHER

lead

University of Cape Town

OTHER

NCT05007795 - Test to Treat TB: Impact of Sputum Sequencing-guided Individualised Therapy on Outcomes in Drug-resistant Tuberculosis | Biotech Hunter | Biotech Hunter